<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586908</url>
  </required_header>
  <id_info>
    <org_study_id>PHP-201-S102</org_study_id>
    <nct_id>NCT03586908</nct_id>
  </id_info>
  <brief_title>PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects</brief_title>
  <official_title>An Open Label, Multiple-dose, Phase 1 Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pH Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>pH Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, multiple-dose, phase 1 clinical trial to evaluate pharmacokinetics,
      pharmacodynamics, safety and tolerability of PHP-201 topical eye drop in Korean and Japanese
      healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary: The evaluation of pharmacokinetic properties of repeating PHP-201 topical eye drop
      Secondary: The evaluation of pharmacodynamic, safety and tolerability of repeating PHP-201
      topical eye drop
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2018</start_date>
  <completion_date type="Actual">March 9, 2018</completion_date>
  <primary_completion_date type="Actual">February 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>1week</time_frame>
    <description>Cmax of PHP-201 &amp; Metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax[Tmax]</measure>
    <time_frame>1week</time_frame>
    <description>Tmax of PHP-201 &amp; Metabolite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Intraocular pressure(IOP)</measure>
    <time_frame>1week</time_frame>
    <description>Mean Change from baseline IOP after 1week</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>PHP-201 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHP-201 0.5%, ophthalmic solution, topical eye drop, OU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PHP-201 0.5% ophthalmic solution (topical eye drop)</intervention_name>
    <description>D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2~D6: PHP-201 0.5% topical eye drop OU TID</description>
    <arm_group_label>PHP-201 0.5%</arm_group_label>
    <other_name>PHP-201 5mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fully informed about the purpose of the study

          2. BMI of 18.0 kg/m² or more and 27.0 kg/m² or less who are between 19 and 50 years of
             age

          3. No congenital or chronic disease and no medically symptomatic findings

        Exclusion Criteria:

          1. Clinically significant disease history or disease history that may affect the
             absorption, distribution, metabolism and excretion of the drug, or ophthalmic corneal
             surgery

          2. had BCVA worse than logMAR 0.2(20/30snellen) or IOP &lt; 10mmHg or &gt;21mmHg in either eye

          3. Abnormalities of clinical examination (SBP, DBP, pulse rate, AST, ALT, Total
             bilirubin, eGFR and Serum test, ECG)

          4. Allergy, drug hypersensitivity and substance abuse

          5. Forbidden drug and diet

          6. Blood donation and transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soojin Kim</last_name>
    <role>Study Director</role>
    <affiliation>pH Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Baek Hospital</name>
      <address>
        <city>Busan</city>
        <state>Busanjin-gu</state>
        <zip>47323</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

